Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$5.60

0.05 (0.90%)

, MRK

Merck

$63.89

0.89 (1.41%)

06:03
05/19/17
05/19
06:03
05/19/17
06:03

Dynavax to present data on SD-101 in combination with KEYTRUDA at ASCO

Dynavax (DVAX) announced that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA, an anti-PD-1 therapy developed by Merck (MRK), will be presented in a poster at the 2017 American Society of Clinical Oncology Annual Meeting. The poster presentation will include updated data from those in the abstract.

DVAX

Dynavax

$5.60

0.05 (0.90%)

MRK

Merck

$63.89

0.89 (1.41%)

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

  • 10

    Aug

DVAX Dynavax
$5.60

0.05 (0.90%)

09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
11/14/16
COWN
11/14/16
NO CHANGE
Target $45
COWN
Outperform
Dynavax's Heplisav may still have a path forward, says Cowen
Cowen analyst Phil Nadeau called the CRL issued to Dynavax regarding its Biologics License Application for Heplisav-B "disappointing and concerning," but also noted that the FDA did not request new trials. While the CRL will push approval until late 2017, in a best case scenario, there may still be a path forward for approval of the drug, said Nadeau, who added that he thinks the stock now looks undervalued. The analyst has an Outperform rating and $45 price target on Dynavax shares.
11/15/16
WBLR
11/15/16
NO CHANGE
Target $17
WBLR
Outperform
William Blair still sees 'good chance' for approval of Dynavax's Heplisav
William Blair analyst Y. Katherine Xu lowered her price target for Dynavax Technologies to $17 from $45 after the company received a second Complete Response Letter from the FDA for the Heplisav Biologics License Application. There is still a "good chance" for Heplisav to garner eventual approval, Xu tells investors in a research note. The lack of apparent concerns regarding rare serious autoimmune events is a plus, the analyst contends. Xu keeps an Outperform rating on Dynavax. She points out the company's immuno-oncology program SD-101 is reading out substantial data starting in 2017. Dynavax closed yesterday down 65% to $4.10.
MRK Merck
$63.89

0.89 (1.41%)

04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.
05/11/17
BMOC
05/11/17
NO CHANGE
BMOC
Merck Keytruda approval positive, says BMO Capital
BMO Capital analyst Alex Arfaei notes that the FDA approved Keytruda + chemo in first line NSCLC. The analyst says that the label is "solid," and he expects "strong uptake" for the drug in the condition, based on his checks with oncologists. The analyst raised his price target on the shares to $74 from $71 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

ARNC

Arconic

$25.21

0.46 (1.86%)

08:47
07/24/17
07/24
08:47
07/24/17
08:47
Hot Stocks
Arconic addresses Grenfell Tower tragedy in earnings results »

In its earnings report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

GLW

Corning

$31.85

0.14 (0.44%)

08:46
07/24/17
07/24
08:46
07/24/17
08:46
Hot Stocks
Corning to collaborate with Gerresheimer on new Corning Valor Glass »

Corning and Gerresheimer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 30

    Jul

FIT

Fitbit

$5.61

-0.15 (-2.60%)

08:45
07/24/17
07/24
08:45
07/24/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SPI

SPI Energy

$0.54

-0.047 (-8.01%)

08:44
07/24/17
07/24
08:44
07/24/17
08:44
Hot Stocks
SPI Energy says Nasdaq grants request to extend stay of suspension in trading »

SPI Energy announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.32

-0.006 (-1.82%)

08:43
07/24/17
07/24
08:43
07/24/17
08:43
Hot Stocks
iBio enters into stock purchase agreement for up to $16M with LPC »

iBio announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$1.11

-0.01 (-0.89%)

08:43
07/24/17
07/24
08:43
07/24/17
08:43
Conference/Events
Cytori Therapeutics to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOH

Bank of Hawaii

$81.45

-0.52 (-0.63%)

08:42
07/24/17
07/24
08:42
07/24/17
08:42
Earnings
Bank of Hawaii reports Q2 EPS $1.05, consensus $1.03 »

Loan and lease balances…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

JCP

J.C. Penney

$5.08

0.08 (1.60%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

08:40
07/24/17
07/24
08:40
07/24/17
08:40
Hot Stocks
J.C. Penney now accepts Apple Pay at all stores »

JCPenney (JCP) has rolled…

JCP

J.C. Penney

$5.08

0.08 (1.60%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

WWD

Woodward

$68.55

-0.87 (-1.25%)

08:39
07/24/17
07/24
08:39
07/24/17
08:39
Conference/Events
Woodward management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

SILC

Silicom

$51.37

0.96 (1.90%)

08:38
07/24/17
07/24
08:38
07/24/17
08:38
Conference/Events
Silicom management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

OTIV

On Track Innovations

$1.47

0.025 (1.74%)

08:38
07/24/17
07/24
08:38
07/24/17
08:38
Hot Stocks
On Track Innovations' Uno-8 contactless reader granted EMVCo Modular approval »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

FNJN

Finjan Holdings

08:38
07/24/17
07/24
08:38
07/24/17
08:38
Hot Stocks
Finjan Holdings says oral arguments to be heard at Court of Appeals on Sep. 8 »

Finjan Holdings (FNJN),…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POL

PolyOne

$38.46

-0.18 (-0.47%)

08:37
07/24/17
07/24
08:37
07/24/17
08:37
Conference/Events
PolyOne management to meet with Northcoast »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 31

    Jul

  • 01

    Aug

ARNC

Arconic

$25.21

0.46 (1.86%)

08:37
07/24/17
07/24
08:37
07/24/17
08:37
Earnings
Arconic sees FY17 EPS $1.15-$1.20, consensus $1.16 »

The company adjusted 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

HIFR

InfraREIT

$19.90

0.2 (1.02%)

08:37
07/24/17
07/24
08:37
07/24/17
08:37
Hot Stocks
Breaking Hot Stocks news story on InfraREIT 

InfraREIT trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SLB

Schlumberger

$66.53

-0.49 (-0.73%)

08:36
07/24/17
07/24
08:36
07/24/17
08:36
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MED

Medifast

$42.11

0.28 (0.67%)

08:36
07/24/17
07/24
08:36
07/24/17
08:36
Hot Stocks
Medifast: Take Shape For Life rebrands to OPTAVIA »

Medifast announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

P

Pandora

$9.47

0.33 (3.61%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

08:36
07/24/17
07/24
08:36
07/24/17
08:36
Periodicals
Spotify near new licensing pact with Warner Music, Reuters reports »

Spotify and Warner Music…

P

Pandora

$9.47

0.33 (3.61%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 01

    Aug

  • 08

    Aug

  • 09

    Aug

  • 05

    Sep

HIFR

InfraREIT

$19.90

0.2 (1.02%)

08:35
07/24/17
07/24
08:35
07/24/17
08:35
Hot Stocks
InfraREIT announces agreement regarding dismissal of pending rate case »

InfraREIT announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DMPI

DelMar Pharmaceuticals

$2.08

0.11 (5.58%)

08:34
07/24/17
07/24
08:34
07/24/17
08:34
Hot Stocks
DelMar Pharmaceuticals: HGRAC approves safety, efficacy study of VAL-083 »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCR

Novocure

08:34
07/24/17
07/24
08:34
07/24/17
08:34
Conference/Events
Novocure management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 31

    Jul

ALV

Autoliv

$106.78

-9.11 (-7.86%)

08:34
07/24/17
07/24
08:34
07/24/17
08:34
Recommendations
Autoliv analyst commentary  »

Autoliv has reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

LMAT

LeMaitre

$28.31

-0.89 (-3.05%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Conference/Events
LeMaitre management to meet with Craig Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 31

    Jul

ARNC

Arconic

$25.21

0.46 (1.86%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Earnings
Arconic reports Q2 EPS ex-items 32c, consensus 26c »

Reports Q2 revenue $3.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

WU

Western Union

$19.09

0.01 (0.05%)

, BP

BP

$34.68

-0.42 (-1.20%)

08:33
07/24/17
07/24
08:33
07/24/17
08:33
Hot Stocks
Western Union announces agreement with BP Australia »

The Western Union Company…

WU

Western Union

$19.09

0.01 (0.05%)

BP

BP

$34.68

-0.42 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.